Search
01/04/2026
Evolving Patterns of EBV-Associated PTLD After Allogeneic Stem Cell Transplantation: Frequency, Characteristics and Outcomes in a Multicenter GETH-TC Study
García-Cadenas, I, Guerreiro, M, Yañez, L, Chorao, P, Martin, F, Suárez-Lledó, M, Pérez, A, Tomás, LG, López, J, Marsal, J, Romero, N, Huguet, M, Zabalza, A, González-Vicent, M, Vázquez, L, Silva, P, Gil, D, Micó-Cerdà, M, Sánchez, P, Filaferro, S, Balsalobre, P, Jiménez-Ubieto, A, Martino, R, Piñana, JL. Evolving Patterns of EBV-Associated PTLD After Allogeneic Stem Cell Transplantation: Frequency, Characteristics and Outcomes in a Multicenter GETH-TC Study. EUROPEAN JOURNAL OF HAEMATOLOGY. 2026; 116(4)DOI:10.1111/ejh.70109. PMID:41502050. IF:2.300(Q2/5D).
01/04/2026
Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT study
Mikulska, M, Tridello, G, Ljungman, P, Styczynski, J, Averbuch, D, Cesaro, S, Knelange, N, Wendel, L, Piñana, JL, Popova, M, Kröger, N, Sengeloev, H, Besley, C, Labussiere-Wallet, H, Yegin, ZA, Greco, R, Baron, F, Yonal-Hindilerden, I, Xhaard, A, Metafuni, E, Verbeek, M, Byrne, J, Toprak, SK, Grassi, A, Vallisa, D, Clay, J, Bufarull, RM, Van Gorkom, G, Sevindik, OG, Wilson, K, de la Camara, R. Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT study. BONE MARROW TRANSPLANTATION. 2026; 61(4)DOI:10.1038/s41409-026-02819-y. PMID:41795056. IF:5.200(Q1/1D).
01/04/2026
Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis
Cortés-Vicente, E, Guerrero, A, Díaz, C, Martínez, E, Toja-Camba, FJ, Abad, MR, Serra, JM, Trillo, JL, Machín, CM, Gil, A. Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis. ADVANCES IN THERAPY. 2026; 43(4)DOI:10.1007/s12325-026-03490-x. PMID:41591648. IF:4.000(Q1/3D).
01/04/2026
Clinical Heterogeneity and Candidate Biomarkers in POLG-Related Mitochondrial Disease
Bermejo-Guerrero, L, Restrepo-Vera, JL, Martin-Jimenez, P, Navarro-Riquelme, M, Garrido-Moraga, R, Ochoa, LE, González-Quintana, A, Hernandez-Lain, A, Castillo-Villalba, J, Morís, G, Muelas, N, García-Arumí, E, González, V, Martínez-Sáez, E, Vesperinas, A, Llansó, L, Juntas-Morales, R, Paradas, C, Kapetanovic, S, Blázquez, A, Martí, R, Arenas, J, Martín, MA, Domínguez-González, C. Clinical Heterogeneity and Candidate Biomarkers in POLG-Related Mitochondrial Disease. Neurology-Genetics. 2026; 12(2)DOI:10.1212/NXG.0000000000200365. PMID:41822038. IF:3.700(Q1/3D).
01/04/2026
Myasthenia gravis in Spain: A survey of specialized neurologists to uncover unmet needs
Cortés-Vicente, E, Casasnovas, C, Juntas, R, Sevilla, T, Pardo, J, de Rivera, FR, Sola, AG. Myasthenia gravis in Spain: A survey of specialized neurologists to uncover unmet needs. NEUROLOGIA. 2026; 41(3)DOI:10.1016/j.nrl.2025.501912. PMID:. IF:3.100(Q2/4D).
01/04/2026
Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
Gregorc, V, Majem, M, Lo Russo, G, Maio, M, Salvagni, S, Gutiérrez-Calderon, V, Gonzalez-Cao, M, Contreras, SS, Koumarianou, A, Bearz, A, Bernabé-Caro, R, Viteri, S, de Sanmamed, MF, Zagouri, F, Bueno, TM, Lazzari, C, Martínez-Recio, S, Giménez-Capitán, A, Zhang, Y, Shan, Y, Zhu, HQ, Zhao, CQ, Shen, HG, Wang, Y, Rosell, R. Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. LANCET ONCOLOGY. 2026; 27(4)DOI:10.1016/S1470-2045(25)00764-8. PMID:41926959. IF:35.900(Q1/1D).